Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000357723

Medchemexpress LLC Imatinib (Mesylate) | 220127-57-1 | 99.9% | C30H35N7O4S | 500 MG
SDP

Catalog No. 5000357723
Encompass_Preferred

Imatinib Mesylate is an orally active tyrosine kinase inhibitor that targets c-Kit, Bcr-Abl, and PDGFR with an IC50 of approximately 100 nM. This compound is intended for research use only.

  • Inhibits c-Kit autophosphorylation, MAPK activation, and Akt activation.
  • Effective against Bcr-Abl, Kit, and PDGFR.
  • Functions as a multi-target inhibitor of v-Abl, c-Kit, Bcr/Abl, Tel/Abl, and PDGFβ receptor.
  • Does not inhibit Src family kinases, c-Fms, Flt3, or EGFR.
  • Inhibits tyrosine phosphorylation and cell growth in various cell lines.
  • Exhibits antileukemic activity in chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).

Catalog No. 50-003-57723 Supplier Medchemexpress LLC Supplier No. HY50946500MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Imatinib Mesylate is an orally active tyrosine kinase inhibitor that targets c-Kit, Bcr-Abl, and PDGFR with an IC50 of approximately 100 nM. This compound is intended for research use only.

  • Inhibits c-Kit autophosphorylation, MAPK activation, and Akt activation.
  • Effective against Bcr-Abl, Kit, and PDGFR.
  • Functions as a multi-target inhibitor of v-Abl, c-Kit, Bcr/Abl, Tel/Abl, and PDGFβ receptor.
  • Does not inhibit Src family kinases, c-Fms, Flt3, or EGFR.
  • Inhibits tyrosine phosphorylation and cell growth in various cell lines.
  • Exhibits antileukemic activity in chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.